Beclometasone/formoterol
| Combination of | |
|---|---|
| Beclometasone dipropionate | Glucocorticoid |
| Formoterol fumarate | Long-acting β2 agonist |
| Clinical data | |
| Trade names | Fostair, others |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
Beclometasone/formoterol, sold under the brand name Fostair among others, is an inhalable fixed-dose combination drug for the treatment of asthma and chronic obstructive pulmonary disease (COPD).[2] It contains beclometasone dipropionate and formoterol fumarate dihydrate. It is inhaled.[2]
It was approved for medical use in the United Kingdom in 2007,[2] and in Australia in February 2020.[5][6] It is on the World Health Organization's List of Essential Medicines.[7]
References
- ^ "Becloform (Cipla Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 16 April 2025. Retrieved 3 May 2025.
- ^ a b c d "Fostair 100/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 3 March 2020. Retrieved 18 July 2020.
- ^ "Fostair 200/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 13 February 2019. Retrieved 18 July 2020.
- ^ "Fostair NEXThaler 200 micrograms/6 micrograms per actuation inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 16 April 2019. Retrieved 18 July 2020.
- ^ "Australian Product Information - Fostair 100/6 (Beclometasone dipropionate and formoterol (eformoterol) fumarate dihydrate) pressurised inhalation solution". Therapeutic Goods Administration (TGA). April 2020. Retrieved 22 September 2020.
- ^ "AusPAR: Beclometasone dipropionate/formoterol (eformoterol) fumarate dihydrate". Therapeutic Goods Administration (TGA). 3 August 2020. Retrieved 22 September 2020.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Further reading
- Foster K, Wong CY (July 2024). "Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: a comprehensive review of Fostair and Trimbow". Journal of Pharmacy and Pharmacology. doi:10.1093/jpp/rgae090. PMID 38954755.